About us

company colture

At Genlumina, we are dedicated to advancing cancer treatments using our unique DNA nanotechnology platform. Our goal is to improve patient outcomes through our light-activated drug.

Meet the team

Donny de Bruin, PhD

Founding Partner & Chief Scientific Officer

Donny de Bruin is a biophysicist specializing in DNA nanotechnology, with a focus on theragnostic applications. He has over a decade of experience in DNA for biosensing, nanoscale positioning, and drug delivery. His research at Leiden University laid the foundation for Genlumina’s technology.

Prof. Dr. D. Bouwmeester

Founding Partner & Patent Officer

Prof. Dr. Bouwmeester, affiliated with Leiden University and UCSB, is a renowned physicist and recipient of the Spinoza Award. With around 200 publications, his work spans quantum optics and biophysics. He has over 15 years of experience in silver cluster DNA technology, highlighting its potential for cancer therapy.

Gerco Kanbier

Founding Partner & Managing Director

Gerco Kanbier has 20 years of entrepreneurial experience in cybersecurity and product development. His analytical skills and rapid prototyping expertise enable the swift transformation of concepts into market-ready solutions. Gerco’s extensive network in primary healthcare positions him to bridge technology and healthcare effectively.

Anja Slikkerveer

Pre-Clinical Drugdeveloper Oncology – Advisory Board

Senior preclinical oncology drug developer with expertise in toxicology and metal-based therapies

Anton Mat

Business Development – Advisory Board

Senior business developer and dealmaker in biotech industry with 25+ years experience.

At Genlumina, we are seeking partnerships to advance our light-activated cancer treatments. If you’re a leader in oncology, pharmaceutical development, or related fields, we invite you to collaborate with us in shaping the future of cancer therapy. Together, we can improve patient outcomes and bring innovative solutions to the market.

You can count on us for using our drug to push the boundaries of what is possible in precision oncology.